Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk
Authors
Keywords
-
Journal
HYPERTENSION
Volume 75, Issue 2, Pages 477-482
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-12-30
DOI
10.1161/hypertensionaha.119.13642
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Inflammatory Therapy with Canakinumab for the Prevention of Hospitalization for Heart Failure
- (2019) Brendan M. Everett et al. CIRCULATION
- Should inflammatory pathways be targeted for the prevention and treatment of hypertension?
- (2019) Setor K Kunutsor et al. HEART
- Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies
- (2019) Ahmad Jayedi et al. HEART
- OUP accepted manuscript
- (2018) EUROPEAN HEART JOURNAL
- Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
- (2018) Paul M Ridker et al. LANCET
- Dietary Docosahexaenoic Acid Reduces Oscillatory Wall Shear Stress, Atherosclerosis, and Hypertension, Most Likely Mediated via an IL‐1–Mediated Mechanism
- (2018) Mabruka A. Alfaidi et al. Journal of the American Heart Association
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension
- (2017) Yeong Hann Ling et al. PHARMACOLOGICAL RESEARCH
- Interleukin-1 Receptor Activation Potentiates Salt Reabsorption in Angiotensin II-Induced Hypertension via the NKCC2 Co-transporter in the Nephron
- (2016) Jiandong Zhang et al. Cell Metabolism
- The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study
- (2014) A. C. Morton et al. EUROPEAN HEART JOURNAL
- Interferon-γ Signaling Inhibition Ameliorates Angiotensin II–Induced Cardiac Damage
- (2012) Lajos Markó et al. HYPERTENSION
- Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
- (2011) Paul M Ridker et al. AMERICAN HEART JOURNAL
- Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice
- (2011) Vinay Bhaskar et al. ATHEROSCLEROSIS
- Central and Peripheral Mechanisms of T-Lymphocyte Activation and Vascular Inflammation Produced by Angiotensin II–Induced Hypertension
- (2010) Paul J. Marvar et al. CIRCULATION RESEARCH
- Inflammation, Immunity, and Hypertension
- (2010) David G. Harrison et al. HYPERTENSION
- Interleukin 17 Promotes Angiotensin II–Induced Hypertension and Vascular Dysfunction
- (2009) Meena S. Madhur et al. HYPERTENSION
- A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II–Dependent Hypertension
- (2009) Steven D. Crowley et al. HYPERTENSION
- Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
- (2009) Janet Chamberlain et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started